CN103860625A - Cranberry extract eye ophthalmic preparation and preparation method and uses thereof - Google Patents
Cranberry extract eye ophthalmic preparation and preparation method and uses thereof Download PDFInfo
- Publication number
- CN103860625A CN103860625A CN201410057007.7A CN201410057007A CN103860625A CN 103860625 A CN103860625 A CN 103860625A CN 201410057007 A CN201410057007 A CN 201410057007A CN 103860625 A CN103860625 A CN 103860625A
- Authority
- CN
- China
- Prior art keywords
- pericarpium citri
- citri tangerinae
- extract
- ophthalmic preparation
- propolis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to a cranberry extract eye ophthalmic preparation and a preparation method and uses thereof, and belongs to the technical field of eye ophthalmic preparations. The technical problem to be solved is to provide a cranberry extract eye ophthalmic preparation. The cranberry extract eye ophthalmic preparation comprises an active ingredient of cranberry extract. The cranberry extract eye ophthalmic preparation can effectively treat, prevent or alleviate cataract, glaucoma, vitreous opacity, macular degeneration, retinopathy, optic atrophy, keratitis, epiphora induced by wind, presbyopia, myopia, visual fatigue, blurred vision, conjunctival burn, conjunctivitis, corneal ulcer, palpebral ecgema, floaters or trachoma and other eye diseases. A novel preparation is provided for treating cataract, glaucoma, vitreous opacity, macular degeneration, retinopathy, optic atrophy, keratitis, epiphora induced by wind, presbyopia, myopia, visual fatigue, blurred vision, conjunctival burn, conjunctivitis, corneal ulcer, palpebral ecgema, floaters or trachoma and other eye diseases, and meets the strong demand of people for loving and protecting eyes.
Description
Technical field
The present invention relates to Pericarpium Citri tangerinae extract ophthalmic preparation and its production and use, belong to ophthalmic preparation technical field.
Background technology
China is the big country of oculopathy: cataract patient is up to 6,000 ten thousand, and glaucoma patients 1,400 ten thousand, myopia 3.5 hundred million, every year because the blind person of oculopathy reaches 4,500,000.Pupil, junior school student's rate of myopia reach respectively 39% and 64%.Eyes are the most important sensory organ of vertebrates.The expert of multiple subjects admits: people should cherish the eyes of oneself by oneself life as Ai Hu! 12 ministries and commissions of China in 1996 combine notice, determine that annual June 6 is for " whole nation Eye-care Day ".Theme as " whole nation Eye-care Day " in 2010 " pay close attention to population below the poverty line eye health, 1,000,000 engineerings are sent light ".
Pericarpium Citri tangerinae is rich in anthocyanidin.In Pericarpium Citri tangerinae, find to exceed 15 kinds of different anthocyanidin.Anthocyanidin can contribute to maintain blood capillary integrity and stable collagen.Anthocyanidin is also strong antioxidant.Numerous clinical studies show Pericarpium Citri tangerinaes is very effective aspect treatment blood circulation discomfort, varicosis and other vein and tremulous pulse discomfort.Anthocyanidin can be stablized phospholipid in endotheliocyte, maintains the integrity of arterial wall structure by increasing collagen and mucopolysaccharide, protects vein and tremulous pulse with this by synthetic.Anthocyanidin prevents gathering and the adhesion of platelet at endothelial cell surface equally.Research also shows that Pericarpium Citri tangerinae can be by stimulating rhodopsin to produce to play the effect of cooperation treatment in diabetes that heme is made peace cause retinopathy.At present, Pericarpium Citri tangerinae product is mainly oral liquid, there are no the relevant report of Pericarpium Citri tangerinae or its extract being made to ophthalmic preparation.
The propolis resin (natural gum) that to be Apis gather from plant spore or trunk, sneaks into a kind of colloidal solid thing with aromatic odor that the secretions of palatine gland on it, wax gland processes.The vitamin B complex of flavone compound, multiple alkene and the terpenoids more than containing 70 kinds in propolis, the aminoacid of trace, trace, abundant mineral and trace element, multiple organic acid.Propolis tonify deficiency for oral administration is weak, change turbid fat, only quench one's thirst; External removing toxic substances and promoting subsidence of swelling.Propolis mainly contains immunoregulatory effect as health food, also has auxiliary antioxidation, regulates the health cares such as blood fat, blood pressure, blood glucose, auxiliary protection gastric mucosa.Prove through scientific research, abundant and unique bioactive substance that propolis is contained, make it have the several functions such as antibacterial, antiinflammatory, antipruritic, antioxidation, enhancing immunity, blood sugar lowering, blood fat reducing, antitumor, promote tissue regeneration, human body is had to medical treatment, health-care effect widely, now become the focus of various countries' scientific research, and become emerging health product and extremely praise highly.The Pharmacopoeia of the People's Republic of China announce it for health care, there are following eight large effects:
One. resisting pathogenic microbes (antibacterial, antiviral);
Two. antitumor;
Three. promote organized renewing;
Four. reduce blood viscosity and improve microcirculation, purify the blood;
Five. hepatoprotective;
Six. antioxidation, elimination free radical;
Seven. immunomodulating;
Eight. endocrine regulation, blood sugar lowering, blood fat and blood pressure.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of Pericarpium Citri tangerinae extract ophthalmic preparation.
Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention, its active component comprises Pericarpium Citri tangerinae extract.
Further, Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention, its active component can be also only Pericarpium Citri tangerinae extract.
Wherein, in order to improve drug effect, Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention, its active component preferably includes propolis and Pericarpium Citri tangerinae extract, wherein, 0.4～1.0 part of propolis by weight, 4.0～8.0 parts of Pericarpium Citri tangerinae extracts.Further, more preferably propolis and Pericarpium Citri tangerinae extract of its active component.
Wherein, in order to improve drug effect, Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention, its active component also preferably includes propolis, Pericarpium Citri tangerinae extract and nanometer selenium, wherein, 0.4～1.0 part of propolis, 4.0～8.0 parts of Pericarpium Citri tangerinae extracts, 0.00001～0.00005 part of nanometer selenium by weight.Further, more preferably propolis, Pericarpium Citri tangerinae extract and nanometer selenium of its active component.
Wherein, in order to improve drug effect, Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention, its active component also preferably includes propolis, Pericarpium Citri tangerinae extract, nanometer selenium, alpha lipoic acid, vitamin E and vitamin C, wherein, 0.4～1.0 part of propolis, 4.0～8.0 parts of Pericarpium Citri tangerinae extracts, 0.00001～0.00005 part of nanometer selenium, 0.1～0.2 part of alpha lipoic acid, 0.2～0.5 part of vitamin E, 1.2～1.8 parts of vitamin Cs by weight.Further, its active component is preferably propolis, Pericarpium Citri tangerinae extract, nanometer selenium, alpha lipoic acid, vitamin E and vitamin C.
Wherein, in order to improve drug effect, Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention, its active component also preferably includes propolis, Pericarpium Citri tangerinae extract, nanometer selenium, alpha lipoic acid, vitamin E, vitamin C, phylloxanthin and astaxanthin, wherein, 0.4～1.0 part of propolis, 4.0～8.0 parts of Pericarpium Citri tangerinae extracts, 0.00001～0.00005 part of nanometer selenium, 0.1～0.2 part of alpha lipoic acid by weight, 0.2～0.5 part of vitamin E, 1.2～1.8 parts of vitamin Cs, 0.02～0.06 part of phylloxanthin, 0.04～0.12 part of astaxanthin; Further preferably, 0.5 part of propolis by weight, 5 parts of Pericarpium Citri tangerinae extracts, 0.00002 part of nanometer selenium, 0.1 part of alpha lipoic acid, 0.3 part of vitamin E, 1.5 parts of vitamin Cs, 0.04 part of phylloxanthin, 0.09 part of astaxanthin.Further, its active component is preferably propolis, Pericarpium Citri tangerinae extract, nanometer selenium, alpha lipoic acid, vitamin E, vitamin C, phylloxanthin and astaxanthin.
Wherein, above-mentioned propolis is preferred water soluble bee glue, and above-mentioned Pericarpium Citri tangerinae extract can be the water solution extract of Pericarpium Citri tangerinae or the alcoholic solution extract of Pericarpium Citri tangerinae, wherein, the alcoholic solution extract of described Pericarpium Citri tangerinae is to extract Pericarpium Citri tangerinae with the alcoholic solution of 30～95wt%, then concentrated, dry forming.
Wherein, above-mentioned propolis, Pericarpium Citri tangerinae extract, nanometer selenium, phylloxanthin, astaxanthin also can directly adopt commercial goods to replace, as propolis can replace with commercially available bosk propolis concentrated solution, Pericarpium Citri tangerinae extract can be with commercially available middle section eye health Pericarpium Citri tangerinae extract, nanometer selenium can be with commercially available middle peasant organic selenium powder or 999Ve selenium, phylloxanthin can be with the international soft capsule of commercially available Kang Hao, and astaxanthin can be with commercially available Haematocoocus Pluvialls.
Wherein, Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention can for eye with liquor, for unguentum, ocular inserts or eye liposome.Further, described ophthalmic preparation is preferably eye liquor, and described eye is eye drop, collyrium or eye injection with liquor.Further, described eye most preferably is eye drop with liquor.
The preparation method of Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention is: by above-mentioned weight portion, each active component is mixed, then add water for injection and pharmaceutically acceptable ophthalmic preparation adjuvant and mix, regulator solution pH value is 7～8.5, then filtration, subpackage, sterilizing, obtain Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention; Wherein, propolis-containing 0.4～1.0g in every 100mL solution.Described pharmaceutically acceptable ophthalmic preparation can be suspending agent, viscosifier, antioxidant etc. with adjuvant.
Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention uses 3-6 time every day, each 1, according to the state of an illness, can suitably increase medication number of times or dosage.
The present invention also provides above-mentioned Pericarpium Citri tangerinae extract ophthalmic preparation in preparation treatment, prevention or has alleviated the purposes in the medicine of cataract, vitreous opacity, degeneration of macula, retinopathy, optic atrophy, keratitis, epiphora induced by wind, presbyopia, myopia, visual fatigue, blurred vision, ambustio conjunctivae, conjunctivitis, corneal ulcer, eczema palpebrae, muscae volitantes or sand holes.
Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention can effectively be treated, prevention or alleviation cataract, glaucoma, vitreous opacity, degeneration of macula, retinopathy, optic atrophy, keratitis, epiphora induced by wind, presbyopia, myopia, visual fatigue, blurred vision, ambustio conjunctivae, conjunctivitis, corneal ulcer, eczema palpebrae, the ocular disease such as muscae volitantes or sand holes, when its active component is compound recipe, because each component has synergistic function, its drug effect is better, the present invention is cataract, glaucoma, vitreous opacity, degeneration of macula, retinopathy, optic atrophy, keratitis, epiphora induced by wind, presbyopia, myopia, visual fatigue, blurred vision, ambustio conjunctivae, conjunctivitis, corneal ulcer, eczema palpebrae, the treatment of the ocular disease such as muscae volitantes or sand holes provides a kind of new preparation, meet people to liking the tight demand of eye eye protection.
Detailed description of the invention
Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention, its active component comprises Pericarpium Citri tangerinae extract.
Further, Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention, its active component can be also only Pericarpium Citri tangerinae extract.
Wherein, in order to improve drug effect, Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention, its active component preferably includes propolis and Pericarpium Citri tangerinae extract, wherein, 0.4～1.0 part of propolis by weight, 4.0～8.0 parts of Pericarpium Citri tangerinae extracts.Further, more preferably propolis and Pericarpium Citri tangerinae extract of its active component.
Wherein, in order to improve drug effect, Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention, its active component also preferably includes propolis, Pericarpium Citri tangerinae extract and nanometer selenium, wherein, 0.4～1.0 part of propolis, 4.0～8.0 parts of Pericarpium Citri tangerinae extracts, 0.00001～0.00005 part of nanometer selenium by weight.Further, more preferably propolis, Pericarpium Citri tangerinae extract and nanometer selenium of its active component.
Wherein, in order to improve drug effect, Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention, its active component also preferably includes propolis, Pericarpium Citri tangerinae extract, nanometer selenium, alpha lipoic acid, vitamin E and vitamin C, wherein, 0.4～1.0 part of propolis, 4.0～8.0 parts of Pericarpium Citri tangerinae extracts, 0.00001～0.00005 part of nanometer selenium, 0.1～0.2 part of alpha lipoic acid, 0.2～0.5 part of vitamin E, 1.2～1.8 parts of vitamin Cs by weight.Further, its active component is preferably propolis, Pericarpium Citri tangerinae extract, nanometer selenium, alpha lipoic acid, vitamin E and vitamin C.
Wherein, in order to improve drug effect, Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention, its active component also preferably includes propolis, Pericarpium Citri tangerinae extract, nanometer selenium, alpha lipoic acid, vitamin E, vitamin C, phylloxanthin and astaxanthin, wherein, 0.4～1.0 part of propolis, 4.0～8.0 parts of Pericarpium Citri tangerinae extracts, 0.00001～0.00005 part of nanometer selenium, 0.1～0.2 part of alpha lipoic acid by weight, 0.2～0.5 part of vitamin E, 1.2～1.8 parts of vitamin Cs, 0.02～0.06 part of phylloxanthin, 0.04～0.12 part of astaxanthin; Further preferably, 0.5 part of propolis by weight, 5 parts of Pericarpium Citri tangerinae extracts, 0.00002 part of nanometer selenium, 0.1 part of alpha lipoic acid, 0.3 part of vitamin E, 1.5 parts of vitamin Cs, 0.04 part of phylloxanthin, 0.09 part of astaxanthin.Further, its active component is preferably propolis, Pericarpium Citri tangerinae extract, nanometer selenium, alpha lipoic acid, vitamin E, vitamin C, phylloxanthin and astaxanthin.
Wherein, above-mentioned propolis is preferred water soluble bee glue, and above-mentioned Pericarpium Citri tangerinae extract can be the water solution extract of Pericarpium Citri tangerinae or the alcoholic solution extract of Pericarpium Citri tangerinae, wherein, the alcoholic solution extract of described Pericarpium Citri tangerinae is to extract Pericarpium Citri tangerinae with the alcoholic solution of 30～95wt%, then concentrated, dry forming.
Wherein, above-mentioned propolis, Pericarpium Citri tangerinae extract, nanometer selenium, phylloxanthin, astaxanthin also can directly adopt commercial goods to replace, as propolis can replace with commercially available bosk propolis concentrated solution, Pericarpium Citri tangerinae extract can be with commercially available middle section eye health Pericarpium Citri tangerinae extract, nanometer selenium can be with commercially available middle peasant organic selenium powder or 999Ve selenium, phylloxanthin can be with the international soft capsule of commercially available Kang Hao, and astaxanthin can be with commercially available Haematocoocus Pluvialls.
Wherein, Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention can for eye with liquor, for unguentum, ocular inserts or eye liposome.Further, described ophthalmic preparation is preferably eye liquor, and described eye is eye drop, collyrium or eye injection with liquor.Further, described eye most preferably is eye drop with liquor.
The preparation method of Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention is: by above-mentioned weight portion, each active component is mixed, then add water for injection and pharmaceutically acceptable ophthalmic preparation adjuvant and mix, regulator solution pH value is 7～8.5, then filtration, subpackage, sterilizing, obtain Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention; Wherein, propolis-containing 0.4～1.0g in every 100mL solution.Described pharmaceutically acceptable ophthalmic preparation can be suspending agent, viscosifier, antioxidant etc. with adjuvant.
Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention uses 3-6 time every day, each 1, according to the state of an illness, can suitably increase medication number of times or dosage.
The present invention also provides above-mentioned Pericarpium Citri tangerinae extract ophthalmic preparation in preparation treatment, prevention or has alleviated the purposes in the medicine of cataract, vitreous opacity, degeneration of macula, retinopathy, optic atrophy, keratitis, epiphora induced by wind, presbyopia, myopia, visual fatigue, blurred vision, ambustio conjunctivae, conjunctivitis, corneal ulcer, eczema palpebrae, muscae volitantes or sand holes.
Below in conjunction with embodiment, the specific embodiment of the present invention is further described, does not therefore limit the present invention among described scope of embodiments.
The preparation of embodiment 1 Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention
According to proportioning in table 1, take Pericarpium Citri tangerinae extract (adopting the alcoholic solution extraction of 75wt% to obtain), add appropriate water for injection, mix, with Palitzsch's buffer solution regulator solution pH value be 7～8.5, every 100mL solution propolis-containing 0.4～1.0g in gained solution, then filtration, subpackage, sterilizing, obtain Pericarpium Citri tangerinae extract eye drop of the present invention.
Table 1
Continued 1
The people such as good fortune Rong Yong, Song Guirong, Wang Yonggui through chemical industry synthetic resin and plastic quality supervision inspection center detects, and Pericarpium Citri tangerinae extract ophthalmic preparation results of property of the present invention is as following table:
Table 2
Wherein, fallow sample and light yellowish brown sample formula are the 10-3 in table 1, and just, what the nanometer system of fallow sample adopted is the organic selenium powder of commercially available middle peasant, and what the nanometer selenium of light yellowish brown sample adopted is commercially available 999Ve selenium.
Test example 1
The eye drops in treatment ocular disease that adopts embodiment 1 to prepare, corneal inflammation, cataract, optic atrophy, vitreous opacity, glaucoma, degeneration of macula, retinopathy, epiphora induced by wind, presbyopia, myopia, visual fatigue, blurred vision, ambustio conjunctivae, conjunctivitis, corneal ulcer, eczema palpebrae, muscae volitantes and sand holes patient treat respectively.Wherein:
Patient A76 year eyes degeneration of macula
Drip with the Pericarpium Citri tangerinae extract ophthalmic preparation that is numbered 1-2 in embodiment 1, dripping with after one month continuously, the dry and astringent symptom of eyes greatly alleviates.
70 years old eye of patient B have ghost image, and vitreous opacity has " muscae volitantes "
Drip with the Pericarpium Citri tangerinae extract ophthalmic preparation that is numbered 3-2 in embodiment 1, dripping with after one month continuously, there is a change for the better for ghost image and " muscae volitantes ".
After patient C79 year cataract operation, there is " muscae volitantes "
Drip with the Pericarpium Citri tangerinae extract ophthalmic preparation that is numbered 6-2 in embodiment 1, dripping with after one month continuously, " muscae volitantes " disappears, and vision rises to 1.0.
Patient D83 year eyes dry and astringent, acid is swollen, itch, often shed tears
Drip with the Pericarpium Citri tangerinae extract ophthalmic preparation that is numbered 9-2 in embodiment 1, dripping with after one month continuously, above-mentioned symptom disappears substantially, and no longer often feels visual fatigue.
Patient E69 year blurred vision, suffers from cataract, and doctor advised carries out cataract operation
Drip with the Pericarpium Citri tangerinae extract ophthalmic preparation that is numbered 10-2 in embodiment 1, dripping with after one month continuously, former vision 0.4 rises to 0.6, and the cataract operation that suggestion is carried out originally also temporarily needn't carry out.
Meanwhile, inventor also uses the oculopathy situation before and after Pericarpium Citri tangerinae extract ophthalmic preparation of the present invention to carry out data statistics to patient, and it the results are shown in Table 3, for the ease of statistics, patient's oculopathy type is divided into following a few class:
I class symptom: the malaise symptoms such as eyes are dry and astringent, acid is swollen, itch, visual fatigue;
II class symptom: ghost image, look the sense of thing mist, blurred vision, " muscae volitantes ";
III class symptom: cataract symptom;
IV class symptom: degeneration of macula, retinopathy;
V class symptom: ambustio conjunctivae, conjunctivitis;
VI class symptom: eczema palpebrae;
VII class symptom: sand holes.
Table 3
Continued 3
Continued 3
Continued 3
As can be seen from Table 3, the oculopathy such as Pericarpium Citri tangerinae extract ophthalmic preparation corneal inflammation of the present invention, cataract, optic atrophy, vitreous opacity, glaucoma, degeneration of macula, retinopathy, epiphora induced by wind, presbyopia, myopia, visual fatigue, blurred vision, ambustio conjunctivae, conjunctivitis, corneal ulcer, eczema palpebrae, muscae volitantes and sand holes all have good therapeutic effect, wherein, active component comprises that the ophthalmic preparation therapeutic effect of propolis, Pericarpium Citri tangerinae extract, nanometer selenium, alpha lipoic acid, vitamin E, vitamin C, phylloxanthin and astaxanthin is best.
Claims (16)
1. Pericarpium Citri tangerinae extract ophthalmic preparation, is characterized in that: its active component comprises Pericarpium Citri tangerinae extract.
2. Pericarpium Citri tangerinae extract ophthalmic preparation according to claim 1, is characterized in that: its active component is Pericarpium Citri tangerinae extract.
3. Pericarpium Citri tangerinae extract ophthalmic preparation according to claim 1, is characterized in that: its active component comprises propolis and Pericarpium Citri tangerinae extract, wherein, and 0.4～1.0 part of propolis by weight, 4.0～8.0 parts of Pericarpium Citri tangerinae extracts.
4. Pericarpium Citri tangerinae extract ophthalmic preparation according to claim 3, is characterized in that: its active component is propolis and Pericarpium Citri tangerinae extract.
5. Pericarpium Citri tangerinae extract ophthalmic preparation according to claim 3, it is characterized in that: its active component comprises propolis, Pericarpium Citri tangerinae extract and nanometer selenium, wherein, 0.4～1.0 part of propolis, 4.0～8.0 parts of Pericarpium Citri tangerinae extracts, 0.00001～0.00005 part of nanometer selenium by weight.
6. Pericarpium Citri tangerinae extract ophthalmic preparation according to claim 5, is characterized in that: its active component is propolis, Pericarpium Citri tangerinae extract and nanometer selenium.
7. Pericarpium Citri tangerinae extract ophthalmic preparation according to claim 3, it is characterized in that: its active component comprises propolis, Pericarpium Citri tangerinae extract, nanometer selenium, alpha lipoic acid, vitamin E and vitamin C, wherein, 0.4～1.0 part of propolis, 4.0～8.0 parts of Pericarpium Citri tangerinae extracts, 0.00001～0.00005 part of nanometer selenium, 0.1～0.2 part of alpha lipoic acid, 0.2～0.5 part of vitamin E, 1.2～1.8 parts of vitamin Cs by weight.
8. Pericarpium Citri tangerinae extract ophthalmic preparation according to claim 7, is characterized in that: its active component is propolis, Pericarpium Citri tangerinae extract, nanometer selenium, alpha lipoic acid, vitamin E and vitamin C.
9. Pericarpium Citri tangerinae extract ophthalmic preparation according to claim 3, it is characterized in that: its active component comprises propolis, Pericarpium Citri tangerinae extract, nanometer selenium, alpha lipoic acid, vitamin E, vitamin C, phylloxanthin and astaxanthin, wherein, 0.4～1.0 part of propolis, 4.0～8.0 parts of Pericarpium Citri tangerinae extracts, 0.00001～0.00005 part of nanometer selenium, 0.1～0.2 part of alpha lipoic acid by weight, 0.2～0.5 part of vitamin E, 1.2～1.8 parts of vitamin Cs, 0.02～0.06 part of phylloxanthin, 0.04～0.12 part of astaxanthin.
10. Pericarpium Citri tangerinae extract ophthalmic preparation according to claim 9, it is characterized in that: 0.5 part of propolis by weight, 5 parts of Pericarpium Citri tangerinae extracts, 0.00002 part of nanometer selenium, 0.1 part of alpha lipoic acid, 0.3 part of vitamin E, 1.5 parts of vitamin Cs, 0.04 part of phylloxanthin, 0.09 part of astaxanthin.
11. according to the Pericarpium Citri tangerinae extract ophthalmic preparation described in any one in claim 3～10, it is characterized in that: described propolis is water-soluble bee glue, described Pericarpium Citri tangerinae extract is the water solution extract of Pericarpium Citri tangerinae or the alcoholic solution extract of Pericarpium Citri tangerinae, wherein, the alcoholic solution extract of described Pericarpium Citri tangerinae is to extract Pericarpium Citri tangerinae with the alcoholic solution of 30～95wt%, then concentrated, dry forming.
12. according to the Pericarpium Citri tangerinae extract ophthalmic preparation described in claim 1～11 any one, it is characterized in that: described ophthalmic preparation is liquor for eye, unguentum, ocular inserts or eye liposome for eye.
13. Pericarpium Citri tangerinae extract ophthalmic preparations according to claim 12, is characterized in that: described ophthalmic preparation is eye liquor, and described eye is eye drop, collyrium or eye injection with liquor.
14. Pericarpium Citri tangerinae extract ophthalmic preparations according to claim 13, is characterized in that: described eye is eye drop with liquor.
The preparation method of the Pericarpium Citri tangerinae extract ophthalmic preparation in 15. claim 1～14 described in any one, it is characterized in that comprising the steps: by weight each active component being mixed, then add appropriate water for injection and pharmaceutically acceptable ophthalmic preparation adjuvant and mix, regulator solution pH value is 7～8.5, then filtration, subpackage, sterilizing, obtain Pericarpium Citri tangerinae extract ophthalmic preparation; Wherein, propolis-containing 0.4～1.0g in every 100ml Pericarpium Citri tangerinae extract ophthalmic preparation.
The purposes of Pericarpium Citri tangerinae extract ophthalmic preparation described in 16. claim 1～15 any one in the medicine of preparation treatment, prevention or alleviation cataract, vitreous opacity, degeneration of macula, retinopathy, optic atrophy, keratitis, epiphora induced by wind, presbyopia, myopia, visual fatigue, blurred vision, ambustio conjunctivae, conjunctivitis, corneal ulcer, eczema palpebrae, muscae volitantes or sand holes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410057007.7A CN103860625A (en) | 2013-02-20 | 2014-02-20 | Cranberry extract eye ophthalmic preparation and preparation method and uses thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310054088.0 | 2013-02-20 | ||
| CN201310054088 | 2013-02-20 | ||
| CN201410057007.7A CN103860625A (en) | 2013-02-20 | 2014-02-20 | Cranberry extract eye ophthalmic preparation and preparation method and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103860625A true CN103860625A (en) | 2014-06-18 |
Family
ID=50900012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410057007.7A Pending CN103860625A (en) | 2013-02-20 | 2014-02-20 | Cranberry extract eye ophthalmic preparation and preparation method and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103860625A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523483A (en) * | 2014-12-06 | 2015-04-22 | 广州一生美网络科技有限公司 | Antioxidant, anti-aging and anti-radiation eye pad composition and preparation method thereof |
| CN105213367A (en) * | 2015-10-28 | 2016-01-06 | 邓宏伟 | Fructus vaccini vitis-idaeae anthocyanidin compositions and in the preparation near-sighted medicine of control or the application of food |
| WO2016184998A1 (en) | 2015-05-21 | 2016-11-24 | Ophtalmis Monaco | Combination of lipoic acid and taurine as osmoprotective agent |
| WO2016185000A1 (en) | 2015-05-21 | 2016-11-24 | Ophtalmis Monaco | Ophthalmic composition comprising lipoic acid and a mucomimetic polymer |
| FR3036284A1 (en) * | 2015-05-21 | 2016-11-25 | Ophtalmis Monaco | LIPOIC ACID AS OSMOPROTECTIVE AGENT |
| US20180264060A1 (en) * | 2017-03-15 | 2018-09-20 | Tokiwa Phytochemical Co., Ltd. | Composition for preventing, or precaution for dry eye |
| CN110882314A (en) * | 2019-11-26 | 2020-03-17 | 李智康 | Eye lotion and preparation method thereof |
| JP2020054396A (en) * | 2015-07-01 | 2020-04-09 | 株式会社東洋新薬 | Composition for protection of retina |
| CN111182911A (en) * | 2017-10-04 | 2020-05-19 | 参天制药株式会社 | Composition for protecting retinal nerve cells comprising processed product of cowberry fruit and processed product of pine bark |
| WO2020109965A1 (en) * | 2018-11-26 | 2020-06-04 | Offhealth S.P.A. | Collyrium containing citrus extract in liposomal form |
| WO2023113586A1 (en) * | 2021-12-15 | 2023-06-22 | Centro De Retina Médica Y Quirúrgica, S.C. | Lipid-based formulation for topical ophthalmic use that contains blueberry extract |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101449819A (en) * | 2007-11-30 | 2009-06-10 | 北京因科瑞斯医药科技有限公司 | Composition capable of releasing asthenopia and preparation method thereof |
-
2014
- 2014-02-20 CN CN201410057007.7A patent/CN103860625A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101449819A (en) * | 2007-11-30 | 2009-06-10 | 北京因科瑞斯医药科技有限公司 | Composition capable of releasing asthenopia and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| 刘淑兰等: "越橘的化学成分与药理活性研究进展", 《中医药学报》 * |
| 庞东渤等: "α-硫辛酸治疗大鼠视网膜缺血再灌注损伤Fas/FasL的表达与细胞凋亡的关系", 《国际眼科杂志》 * |
| 张宏等编著: "《健康需要维生素》", 31 December 2003, 辽宁科学技术出版社 * |
| 戴光强著: "《中年保健全新指南》", 31 December 2006, 上海教育出版社 * |
| 胡庆军等: "越橘提取物改善糖尿病视网膜病变黄斑水肿对比敏感度和眩光功能", 《眼科新进展》 * |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523483A (en) * | 2014-12-06 | 2015-04-22 | 广州一生美网络科技有限公司 | Antioxidant, anti-aging and anti-radiation eye pad composition and preparation method thereof |
| WO2016184998A1 (en) | 2015-05-21 | 2016-11-24 | Ophtalmis Monaco | Combination of lipoic acid and taurine as osmoprotective agent |
| WO2016185000A1 (en) | 2015-05-21 | 2016-11-24 | Ophtalmis Monaco | Ophthalmic composition comprising lipoic acid and a mucomimetic polymer |
| FR3036284A1 (en) * | 2015-05-21 | 2016-11-25 | Ophtalmis Monaco | LIPOIC ACID AS OSMOPROTECTIVE AGENT |
| US11224588B2 (en) | 2015-05-21 | 2022-01-18 | Ophtalmis Monaco | Combination of lipoic acid and taurine as osmoprotective agent |
| US10940206B2 (en) | 2015-05-21 | 2021-03-09 | Ophtalmis Monaco | Ophthalmic composition comprising lipoic acid and a mucomimetic polymer |
| JP2020054396A (en) * | 2015-07-01 | 2020-04-09 | 株式会社東洋新薬 | Composition for protection of retina |
| CN105213367A (en) * | 2015-10-28 | 2016-01-06 | 邓宏伟 | Fructus vaccini vitis-idaeae anthocyanidin compositions and in the preparation near-sighted medicine of control or the application of food |
| US11154581B2 (en) | 2017-03-15 | 2021-10-26 | Tokiwa Phytochemical Co., Ltd. | Method for improvement of stiff neck and shoulders |
| US20180264060A1 (en) * | 2017-03-15 | 2018-09-20 | Tokiwa Phytochemical Co., Ltd. | Composition for preventing, or precaution for dry eye |
| CN111182911A (en) * | 2017-10-04 | 2020-05-19 | 参天制药株式会社 | Composition for protecting retinal nerve cells comprising processed product of cowberry fruit and processed product of pine bark |
| WO2020109965A1 (en) * | 2018-11-26 | 2020-06-04 | Offhealth S.P.A. | Collyrium containing citrus extract in liposomal form |
| CN110882314B (en) * | 2019-11-26 | 2021-11-02 | 李智康 | Eye lotion and preparation method thereof |
| CN110882314A (en) * | 2019-11-26 | 2020-03-17 | 李智康 | Eye lotion and preparation method thereof |
| WO2023113586A1 (en) * | 2021-12-15 | 2023-06-22 | Centro De Retina Médica Y Quirúrgica, S.C. | Lipid-based formulation for topical ophthalmic use that contains blueberry extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103860625A (en) | Cranberry extract eye ophthalmic preparation and preparation method and uses thereof | |
| CN109091675B (en) | Compound low-concentration atropine medicine eye drops and preparation method thereof | |
| CN102225087A (en) | Xanthophyll compound preparation with powerful eye-protecting effect | |
| CN107802561A (en) | One kind nursing eye gel and its production method | |
| CN104147081A (en) | Blueberry lutein soft capsule for improving eyesight and manufacturing method thereof | |
| CN102753163B (en) | Composition comprising as active ingredient l-carnitine in combination with hydroxykynurenine-o-beta-dl-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation | |
| CN103300373A (en) | Lutein and procyanidine composite soft capsule and preparation method thereof | |
| CN110496215A (en) | A kind of aqueous ophthalmic solution and preparation method thereof for treating presbyopia | |
| CN101890116A (en) | Anthocyanin health-care eye drops and preparation method thereof | |
| CN101416741A (en) | Health-care food for relieving visual fatigue | |
| CN103316032B (en) | Compositions containing hydroxytyrosol and application thereof | |
| ES2829630T3 (en) | Compositions based on active ingredients of plant origin with protective action for the eyes | |
| CN105106286A (en) | Health product with effects of protecting eyes and improving eyesight | |
| CN109010790A (en) | A kind of composition and its application for improving eye strain | |
| CN106692187A (en) | Composition for improving visuognosis persistence and protecting eye health | |
| CN105520137A (en) | Healthy food with functions of relieving asthenopia and protecting eyesight | |
| CN101612161A (en) | A kind of eye medicine combination and preparation thereof | |
| CN102150860B (en) | Composition for easing visual fatigue and assisting in improving memory | |
| CN106963770A (en) | It is a kind of to be used to prevent and treat eye drops of drying property angle/conjunctivitis and its production and use | |
| CN101785854B (en) | Lutein multivitamin nutrition health care medicine composition and preparation method and applications thereof | |
| CN104857287A (en) | Traditional Chinese medicine eye-drop for treating xeroma and preparation method thereof | |
| CN104474509A (en) | Medicine patch for conditioning eye refraction and preparation method of medicine patch | |
| CN101040893A (en) | Blueberry capsule for protecting vision and the preparing method | |
| CN110559314A (en) | Composition for protecting eyesight | |
| CN104436156A (en) | Eyesight protective agent xanthophyll eye preparation and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140618 |
|
| WD01 | Invention patent application deemed withdrawn after publication |